Let's Talk

03 9602 1230

EPS of $20 by 2025? Progress and Profile to Power Paradigm’s Share Price

Paradigm Biopharmaceuticals (PAR.ASX) have $108M in cash, no debt and are well advanced in the progression of clinical trials in addressable markets worth up to as much as $36B p.a. The next two years are particularly exciting for Paradigm Biopharmaceuticals as they are set to announce:

  • Complete recruitment of 1150 patients for the stage 3-clinical OA trials.
  • Embarkment of stage 3 clinical trials for MPS
  • Potential for Australian approval to begin treatment – which would lead to first significant earnings.
  • Addition of Paradigm to the ASX 300 – leading to greater coverage
  • Publication of results in peer-reviewed journals.

Each of those pieces of news could drive significantly more interest in the company, and result in a materially higher share price.

Click here to read the full article in Livewire.

Return to Insights
Our Location

Level 9 365 Little Collins Street Melbourne VIC 3000

Contact Details

ROB HAY
Head of Distribution & Investor Relations
M: 0423 345 975
E: rhay@csvf.com.au

The Collins Street Value Fund (CSVF) is managed by Collins St Asset Management Pty Ltd (CSAM) AFSL 468935. CSAM is authorised to provide financial services to wholesale clients only (as set out in section 761G (7) of the Corporations Act 2001).

Start a conversation with us

Speak with our Equity Market Specialists about how we drive superior investment returns through patience, objectivity and freedom. Available after hours by appointment.

©2023 Collins St Asset Management Pty Ltd – Privacy Policy

Available to Wholesale Investors. Past performance is not a reliable indicator of future performance. AFSL 468935.  Our Privacy Policy can be accessed here.

Information from Mercer has been obtained from a range of third party sources. While the information is believed to be reliable, Mercer has not sought to verify it independently. As such, Mercer makes no representations or warranties as to the accuracy of the information presented and takes no responsibility or liability (including for indirect, consequential or incidental damages), for any error, omission or inaccuracy in the data supplied by any third party.

Facebook